Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aim Immunotech Inc (NY: AIM )

0.2079 -0.0101 (-4.63%)
Streaming Delayed Price Updated: 10:48 AM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aim Immunotech Inc

< Previous 1 2 3 4 Next >
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
Via Benzinga
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape... 
Via Benzinga
A Preview Of AIM ImmunoTech's Earnings
AIM ImmunoTech (AMEX:AIM) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that AIM ImmunoTech... 
Via Benzinga
Preview: AIM ImmunoTech's Earnings
AIM ImmunoTech (AMEX:AIM) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that AIM ImmunoTech... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers for today as we prepare for a busy day of trading on Tuesday! 
Via InvestorPlace
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and MicroSafe Group DMCC reported EPA approval for... 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
26 Stocks Moving in Monday's Pre-Market Session
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial... 
Via Benzinga
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday. Clarus Therapeutics Holdings, Inc. (NASDAQ:... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning! 
Via InvestorPlace
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting
AIM ImmunoTech Inc (NYSE: AIM) has  
Via Benzinga
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
AIM ImmunoTech Inc (NYSE: AIM) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic... 
Via Benzinga
AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease
AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two... 
Via Benzinga
Exposures COVID-19 Product Safety
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive... 
Via Benzinga
Exposures Product Safety
AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction
AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd... 
Via Benzinga
Earnings Scheduled For May 14, 2021
Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report... 
Via Benzinga
AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.